上海精神医学最新文献

英文中文

Research Status and Strategies for Cognitive Function in Schizophrenia. 精神分裂症认知功能的研究现状与对策

Shanghai archives of psychiatry

Pub Date : 2018-06-25 DOI: 10.11919/j.issn.1002-0829.218008

Ke Ma, Chuan Shi

Cognit ion is divided into neurocognit ion and social cognition, both of which are interconnected w i t h e a c h o t h e r a n d y e t a r e m u t u a l l y independent. Neurocognition, which is based on neuroanatomical structures, function connections, neuroelectrophysiology and molecular biology, is the basis of the human brain and the reflection of advanced integrative neural function in behavioral science. Social cognition is the cognitive process of perceiving others’ emotions or intentions and making responses. It took almost a century from 1893 when Kraepelin first described the cognitive impairment of schizophrenia as “Dementia praecox” to the last two decades when the research on cognition recaptured people’s attention. It is commonly accepted that cognitive impairment is one of the symptoms of schizophrenia that is characterized by cognitive impairment in learning, memory, attention, speed of information processing, executive function and social cognition, and the severity of cognitive impairment in schizophrenia is often worse than that of healthy controls. Studies found that neurocognition had an impact on the variance of functional outcome in schizophrenia patients with an effect size of 20%-60%. According to a meta-analysis, 8 out of 9 studies showed that social cognition was also related to the functional outcome in schizophrenia patients. Although the research on cognitive impairment of schizophrenia has made great progress in recent years, there are still many deficiencies to be solved, including a lack of depth and undesirable results that we need to work together to solve.

{"title":"Research Status and Strategies for Cognitive Function in Schizophrenia.","authors":"Ke Ma, Chuan Shi","doi":"10.11919/j.issn.1002-0829.218008","DOIUrl":"https://doi.org/10.11919/j.issn.1002-0829.218008","url":null,"abstract":"Cognit ion is divided into neurocognit ion and social cognition, both of which are interconnected w i t h e a c h o t h e r a n d y e t a r e m u t u a l l y independent. Neurocognition, which is based on neuroanatomical structures, function connections, neuroelectrophysiology and molecular biology, is the basis of the human brain and the reflection of advanced integrative neural function in behavioral science. Social cognition is the cognitive process of perceiving others’ emotions or intentions and making responses. It took almost a century from 1893 when Kraepelin first described the cognitive impairment of schizophrenia as “Dementia praecox” to the last two decades when the research on cognition recaptured people’s attention. It is commonly accepted that cognitive impairment is one of the symptoms of schizophrenia that is characterized by cognitive impairment in learning, memory, attention, speed of information processing, executive function and social cognition, and the severity of cognitive impairment in schizophrenia is often worse than that of healthy controls. Studies found that neurocognition had an impact on the variance of functional outcome in schizophrenia patients with an effect size of 20%-60%. According to a meta-analysis, 8 out of 9 studies showed that social cognition was also related to the functional outcome in schizophrenia patients. Although the research on cognitive impairment of schizophrenia has made great progress in recent years, there are still many deficiencies to be solved, including a lack of depth and undesirable results that we need to work together to solve.","PeriodicalId":21886,"journal":{"name":"Shanghai archives of psychiatry","volume":"30 3","pages":"199-201"},"PeriodicalIF":0.0,"publicationDate":"2018-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.11919/j.issn.1002-0829.218008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37045489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Posterior Fossa Arachnoid Cyst Presenting as Negative Symptoms of Psychosis. 后窝蛛网膜囊肿表现为精神病的阴性症状。

Shanghai archives of psychiatry

Pub Date : 2018-06-25 DOI: 10.11919/j.issn.1002-0829.218005

Soumitra DAS

Arachnoid cysts are benign congenital malformations, making up 1% among all the space occupying lesions (SOL). Sylvain fissure is the most common place (50%) but it can happen in any place. Patients might complain of a headache, ataxia, seizures, dizziness, and visual changes etc. The common psychiatric symptoms are psychosis, alexithymia, attention deficit and hyperactivity disorder, paranoid delusions, obsessive religiosity, sense of guilt or ruin, hallucinations, depression, insomnia, irritability and cognitive alterations etc. Recently, we presented a case of an arachnoid cyst in the right middle cranial fossa compressing temporal lobe presenting as the positive symptoms of psychosis. Here, we are presenting a case of posterior fossa arachnoid cyst which presented as severe negative symptoms.

引用次数: 1

Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia. 奥氮平与其他第二代抗精神病药物在改善精神分裂症患者洞察力和停药率方面的比较。

Shanghai archives of psychiatry

Pub Date : 2018-06-25 DOI: 10.11919/j.issn.1002-0829.217087

Hongbo He, Yanling Zhou, Mingzhe Yang, Xiongxiong Li, Yu-Tao Xiang, Jiandong Luo

Background: In the last decade, olanzapine became widely used in mental health service worldwide even after being criticized for its metabolic side effects. Patients with schizophrenia on olanzapine were usually found to stay on their medications longer than the other second-generation antipsychotics (SGAs) except clozapine. The reason for this is unknown.

Objective: This prospective study compared the influences of olanzapine and other SGAs except clozapine on improving insight and medication discontinuation rate in schizophrenia.

Methods: A total of 148 patients with schizophrenia medically indicated for initiation of treatment with olanzapine or other SGAs were evaluated for symptoms, insight, attitudes toward medication, side effects, body weight and fasting lipid and glucose parameters at admission and before discharge, and follow-up calls one-year after discharge documented whether they were regularly taking prescribed psychotropic medication or not.

Results: After an average of 72.8 days of inpatient treatment, the olanzapine and other SGAs group exhibited similar levels of symptom improvement with an average reduction of 28.7 in the Positive and Negative Syndrome Scale (PANSS) total score. The Olanzapine group exhibited better improvement in insight assessed using the G12 item of PANSS and Insight and Treatment Attitudes Questionnaire (ITAQ), more metabolic side effects indexed with total cholesterol, triglycerides levels and weight gain, and a lower medication discontinuation rate than the other SGAs group.

Conclusion: Although general symptom improvement was similar, olanzapine significantly improved insight and presented less medication discontinuation compared to other SGAs, which might partially explain why patients on olanzapine stayed longer on their medications.

背景:近十年来，奥氮平在受到代谢副作用的批评后，在世界范围内被广泛应用于精神卫生服务。服用奥氮平的精神分裂症患者通常比除氯氮平外的其他第二代抗精神病药物(SGAs)服药时间更长。其原因尚不清楚。目的:本前瞻性研究比较奥氮平与除氯氮平外的其他SGAs对精神分裂症患者改善洞察力和停药率的影响。方法:对148例精神分裂症患者在入院和出院时的症状、见解、用药态度、副作用、体重、空腹血脂和血糖指标进行评估，并在出院后1年进行随访，记录患者是否定期服用处方精神药物。结果:在平均72.8天的住院治疗后，奥氮平组和其他SGAs组的症状改善水平相似，阳性和阴性综合征量表(PANSS)总分平均下降28.7分。使用PANSS的G12项目和洞察力和治疗态度问卷(ITAQ)评估，奥氮平组在洞察力方面表现出更好的改善，以总胆固醇，甘油三酯水平和体重增加为指标的代谢副作用更多，停药率低于其他SGAs组。结论:虽然总体症状改善相似，但与其他SGAs相比，奥氮平显著改善了洞察力，停药的情况更少，这可能部分解释了为什么服用奥氮平的患者服药时间更长。

{"title":"Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia.","authors":"Hongbo He, Yanling Zhou, Mingzhe Yang, Xiongxiong Li, Yu-Tao Xiang, Jiandong Luo","doi":"10.11919/j.issn.1002-0829.217087","DOIUrl":"https://doi.org/10.11919/j.issn.1002-0829.217087","url":null,"abstract":"Background: In the last decade, olanzapine became widely used in mental health service worldwide even after being criticized for its metabolic side effects. Patients with schizophrenia on olanzapine were usually found to stay on their medications longer than the other second-generation antipsychotics (SGAs) except clozapine. The reason for this is unknown.Objective: This prospective study compared the influences of olanzapine and other SGAs except clozapine on improving insight and medication discontinuation rate in schizophrenia.Methods: A total of 148 patients with schizophrenia medically indicated for initiation of treatment with olanzapine or other SGAs were evaluated for symptoms, insight, attitudes toward medication, side effects, body weight and fasting lipid and glucose parameters at admission and before discharge, and follow-up calls one-year after discharge documented whether they were regularly taking prescribed psychotropic medication or not.Results: After an average of 72.8 days of inpatient treatment, the olanzapine and other SGAs group exhibited similar levels of symptom improvement with an average reduction of 28.7 in the Positive and Negative Syndrome Scale (PANSS) total score. The Olanzapine group exhibited better improvement in insight assessed using the G12 item of PANSS and Insight and Treatment Attitudes Questionnaire (ITAQ), more metabolic side effects indexed with total cholesterol, triglycerides levels and weight gain, and a lower medication discontinuation rate than the other SGAs group.Conclusion: Although general symptom improvement was similar, olanzapine significantly improved insight and presented less medication discontinuation compared to other SGAs, which might partially explain why patients on olanzapine stayed longer on their medications.","PeriodicalId":21886,"journal":{"name":"Shanghai archives of psychiatry","volume":"30 3","pages":"178-187"},"PeriodicalIF":0.0,"publicationDate":"2018-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.11919/j.issn.1002-0829.217087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37045487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Research Progress in Biological Studies of Schizophrenia in China in 2017. 2017年中国精神分裂症生物学研究进展。

Shanghai archives of psychiatry

Pub Date : 2018-06-25 DOI: 10.11919/j.issn.1002-0829.218041

Dengtang Liu, Haixin Cen, Kaida Jiang, Yifeng Xu

Schizophrenia is a severe mental disorder and its etiology and pathological mechanism are unknown. This article mainly introduces the progress of biological studies of schizophrenia in China in 2017, including neuroimaging, genetics, and immunology studies. It also introduces the research progress of high-risk psychotic syndrome and physiotherapy.

精神分裂症是一种严重的精神障碍，其病因和病理机制尚不清楚。本文主要介绍2017年我国精神分裂症生物学研究进展，包括神经影像学、遗传学、免疫学研究。同时介绍了高危精神综合征和物理治疗的研究进展。

引用次数: 0

A Comparison Study of Working Memory Deficits between Patients with Methamphetamine-Associated Psychosis and Patients with Schizophrenia. 甲基苯丙胺相关精神病患者与精神分裂症患者工作记忆缺陷的比较研究。

Shanghai archives of psychiatry

Pub Date : 2018-06-25 DOI: 10.11919/j.issn.1002-0829.217166

Hong Gan, Zhenhua Song, Peiwei Xu, Hang Su, Yingying Pan, Min Zhao, Dengtang Liu

Background: Both patients with methamphetamine-associated psychosis (MAP) and patients with schizophrenia suffer from obvious cognitive deficits in working memory, and this affects the functional prognosis of patients.

Aim: This study is to investigate the difference of working memory deficits between patients with MAP and patients with schizophrenia, especially the difference of central executive system function, and the relevance of working memory deficits and clinical characteristics.

Methods: Twenty-eight male patients with MAP and twenty-eight patients with schizophrenia were recruited. The working memory of subjects was evaluated with the n-back task edited and adapted from English language materials. The positive syndrome scale of PANSS and CGI were employed to assess psychotic symptoms and the severity of patients.

Results: According to the results of repeated measure variance analysis, it was found that both the between-group variable (group) and within-group variable (n) had significant main effects, and the interaction between the between-group variable and the within-group variable was also significant. After Z-transformation, mean (sd) working memory scores of patients with MAP and schizophrenia were 0.91 (0.77) and -0.91 (2.11) respectively, and the difference between these two groups were statistically significant (F=19.253, p<0.001). The relevance between working memory deficits and clinical characteristics was low in both the patients with MAP and patients with schizophrenia.

Conclusion: Patients with MAP were better at regulating, updating, executing and controlling active information than patients with schizophrenia.

背景:甲基苯丙胺相关精神病(MAP)患者和精神分裂症患者均存在明显的工作记忆认知缺陷，影响患者的功能预后。目的:探讨MAP患者与精神分裂症患者工作记忆缺陷的差异，特别是中枢执行系统功能的差异，以及工作记忆缺陷与临床特征的相关性。方法:选取男性MAP患者28例，精神分裂症患者28例。实验对象的工作记忆采用编辑和改编自英语材料的n-back任务进行评估。采用PANSS阳性综合征量表和CGI量表评估患者的精神病症状和严重程度。结果:根据重复测量方差分析的结果，发现组间变量(group)和组内变量(n)均有显著的主效应，组间变量与组内变量之间的交互作用也显著。经z转换后，MAP组和精神分裂症组的工作记忆平均(sd)评分分别为0.91(0.77)和-0.91(2.11)，两组间差异有统计学意义(F=19.253, p)。结论:MAP组在活动信息的调节、更新、执行和控制方面优于精神分裂症组。

{"title":"A Comparison Study of Working Memory Deficits between Patients with Methamphetamine-Associated Psychosis and Patients with Schizophrenia.","authors":"Hong Gan, Zhenhua Song, Peiwei Xu, Hang Su, Yingying Pan, Min Zhao, Dengtang Liu","doi":"10.11919/j.issn.1002-0829.217166","DOIUrl":"https://doi.org/10.11919/j.issn.1002-0829.217166","url":null,"abstract":"Background: Both patients with methamphetamine-associated psychosis (MAP) and patients with schizophrenia suffer from obvious cognitive deficits in working memory, and this affects the functional prognosis of patients.Aim: This study is to investigate the difference of working memory deficits between patients with MAP and patients with schizophrenia, especially the difference of central executive system function, and the relevance of working memory deficits and clinical characteristics.Methods: Twenty-eight male patients with MAP and twenty-eight patients with schizophrenia were recruited. The working memory of subjects was evaluated with the n-back task edited and adapted from English language materials. The positive syndrome scale of PANSS and CGI were employed to assess psychotic symptoms and the severity of patients.Results: According to the results of repeated measure variance analysis, it was found that both the between-group variable (group) and within-group variable (n) had significant main effects, and the interaction between the between-group variable and the within-group variable was also significant. After Z-transformation, mean (sd) working memory scores of patients with MAP and schizophrenia were 0.91 (0.77) and -0.91 (2.11) respectively, and the difference between these two groups were statistically significant (F=19.253, p<0.001). The relevance between working memory deficits and clinical characteristics was low in both the patients with MAP and patients with schizophrenia.Conclusion: Patients with MAP were better at regulating, updating, executing and controlling active information than patients with schizophrenia.","PeriodicalId":21886,"journal":{"name":"Shanghai archives of psychiatry","volume":"30 3","pages":"168-177"},"PeriodicalIF":0.0,"publicationDate":"2018-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/7e/sap-30-168.PMC6410400.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37045486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Hypokalemia Caused by Quetiapine and Risperidone Treatment in Schizophrenia: A Case Report. 奎硫平和利培酮治疗精神分裂症所致低钾血症1例。

Shanghai archives of psychiatry

Pub Date : 2018-06-25 DOI: 10.11919/j.issn.1002-0829.217168

Qiongwei Yang, Xiaoyun Guo, Dengtang Liu

Hypokalemia can cause abnormalities in multiple systems. Long term use of antipsychotic medications can lead to electrolyte imbalance, including hypokalemia. We report a 49-year-old female patient with schizophrenia who developed hypokalemia after oral quetiapine and risperidone treatments. Her blood potassium became normal after she switched to another antipsychotic drug (amisulpride). In addition, we discuss the potential mechanism of antipsychotic drugs leading to hypokalemia and clinical cautions.

低钾血症可引起多个系统的异常。长期服用抗精神病药物可导致电解质失衡，包括低钾血症。我们报告了一位49岁女性精神分裂症患者，在口服喹硫平和利培酮治疗后出现低钾血症。改用另一种抗精神病药物(氨硫pride)后，她的血钾恢复正常。此外，我们还讨论了抗精神病药物导致低钾血症的潜在机制和临床注意事项。

引用次数: 3

Assessing the Accuracy of Diagnostic Tests. 评估诊断测试的准确性。

Shanghai archives of psychiatry

Pub Date : 2018-06-25 DOI: 10.11919/j.issn.1002-0829.218052

Fangyu Li, Hua He

Gold standard tests are usually used for diagnosis of a disease, but the gold standard tests may not be always available or cannot be administrated due to many reasons such as cost, availability, ethical issues etc. In such cases, some instruments or screening tools can be used to diagnose the disease. However, before the screening tools can be applied, it is crucial to evaluate the accuracy of these screening tools compared to the gold standard tests. In this assay, we will discuss how to assess the accuracy of a diagnostic test through an example using R program.

金标准测试通常用于疾病的诊断，但由于成本、可用性、道德问题等诸多原因，金标准测试可能并不总是可用或无法实施。在这种情况下，可以使用一些仪器或筛查工具来诊断疾病。然而，在应用筛选工具之前，与金标准测试相比，评估这些筛选工具的准确性至关重要。在这个实验中，我们将通过一个使用R程序的例子来讨论如何评估诊断测试的准确性。

引用次数: 90

IN THIS ISSUE 本期

Shanghai archives of psychiatry

Pub Date : 2018-06-25 DOI: 10.11919/j.issn.1002-0829.218048

Our staff is now in preparation for the upcoming launch date with the BMJ Publishing Group. The first important step is to accept and review all the articles in English using the ScholarOne system. Use of this system will be implemented starting from June. We believe that the new use of the ScholarOne system will help improve our manuscript reviewing process and increase the quality of published articles. Schizophrenia is a kind of chronic brain disease with unclear etiology, unsatisfactory effect of treatments, and poor functional outcomes. The present issue is focused on introducing research reports related to schizophrenia. It starts with Liu and colleagues introducing the biological research progress of schizophrenia in China with a special focus on neuroimaging research (resting state functional magnetic resonance imaging (fMRI) and functional connectivity, diffusion tensor imaging, and genetic imaging research), genetic research, and immunological research in 2017. They pointed out that applying neuroimaging technology to study schizophrenia is the most active research field in China in the past year. They also give a brief introduction of research progress of ultra-high-risk state populations. In the conclusion, the author commented on possible directions for future research.

我们的员工正在为即将到来的BMJ出版集团发布日期做准备。第一个重要步骤是使用ScholarOne系统接受并审查所有英文文章。该系统将从6月开始使用。我们相信，ScholarOne系统的新使用将有助于改进我们的稿件审核流程，提高已发表文章的质量。精神分裂症是一种病因不明、治疗效果不理想、功能不良的慢性脑疾病。本期重点介绍与精神分裂症相关的研究报告。首先，刘及其同事介绍了2017年中国精神分裂症的生物学研究进展，重点是神经影像学研究（静息状态功能磁共振成像（fMRI）和功能连接、扩散张量成像和遗传影像学研究）、遗传学研究和免疫学研究。他们指出，应用神经成像技术研究精神分裂症是近一年来中国最活跃的研究领域。他们还简要介绍了超高风险州人群的研究进展。在结论中，作者评论了未来研究的可能方向。

{"title":"IN THIS ISSUE","authors":"","doi":"10.11919/j.issn.1002-0829.218048","DOIUrl":"https://doi.org/10.11919/j.issn.1002-0829.218048","url":null,"abstract":"Our staff is now in preparation for the upcoming launch date with the BMJ Publishing Group. The first important step is to accept and review all the articles in English using the ScholarOne system. Use of this system will be implemented starting from June. We believe that the new use of the ScholarOne system will help improve our manuscript reviewing process and increase the quality of published articles. Schizophrenia is a kind of chronic brain disease with unclear etiology, unsatisfactory effect of treatments, and poor functional outcomes. The present issue is focused on introducing research reports related to schizophrenia. It starts with Liu and colleagues introducing the biological research progress of schizophrenia in China with a special focus on neuroimaging research (resting state functional magnetic resonance imaging (fMRI) and functional connectivity, diffusion tensor imaging, and genetic imaging research), genetic research, and immunological research in 2017. They pointed out that applying neuroimaging technology to study schizophrenia is the most active research field in China in the past year. They also give a brief introduction of research progress of ultra-high-risk state populations. In the conclusion, the author commented on possible directions for future research.","PeriodicalId":21886,"journal":{"name":"Shanghai archives of psychiatry","volume":"30 1","pages":"145 - 146"},"PeriodicalIF":0.0,"publicationDate":"2018-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41715414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Association Study on the Cognitive Function and the Cerebral Grey Matter Volume of Patients with First-Episode Schizophrenia. 首发精神分裂症患者认知功能与脑灰质体积的相关性研究。

Shanghai archives of psychiatry

Pub Date : 2018-06-25 DOI: 10.11919/j.issn.1002-0829.217138

Xinyue Zhang, Jingjing Yao, Yiding Lv, Xiaoxin Zhao, Yuan Li, Yuxiu Sui, Dai Zhiping

Background: The impairment of cognitive function is one of the core symptoms in schizophrenia, and the degree of recovery is closely related to whether patients are able to rejoin society successfully.

Objective: This study was to clarify the correlation between cognitive function and cerebral grey matter volume in schizophrenia.

Methods: The neuro-cognitive functions of thirty-seven patients with first-episode schizophrenia (the patient group) and thirty healthy controls (the control group) was evaluated with the Clock Drawing Test, Trail Marking Test, Digit Span Test, Auditory Verbal Learning Test, Wisconsin Card Sorting Test, Verbal Fluency Test, Semantic Similarity Test and Stroop Color-Word Test. The facial emotion cognitive task was employed to assess the facial emotion cognitive functions of thirty-two patients with first-episode schizophrenia (the patient group) and 29 healthy controls (the control group). The psychotic symptoms of patients with first-episode schizophrenia were evaluated using the Positive and Negative Syndrome Scale (PANSS). The brain imaging data of the patient group and control group were collected using the magnetic resonance imagine (MRI).

Results: The difference between the patient group and the control group in the results of Clock Drawing Test, Trail Marking Test, Digit Span Test, Auditory Verbal Learning Test, Wisconsin Card Sorting Test, Verbal Fluency Test, Semantic Similarity Test and Stroop Color-Word Test's reaction time were significant. These two groups' Slopes in the facial emotion cognitive task were also significantly different from each other. According to the comparison of cerebral grey matter volume between the patient group and the control group, it was found that the grey matter volume of the patient group increased in the left superior frontal gyrus, and decreased in the left occipital gyrus, lingual gyrus and upper cerebellum. Based on the analyses of neuro-cognitive data and brain imaging data of the patient group, the scores of the number of correct responses in Stroop Color-Word Test's Card C were negatively correlated with grey matter volumes of the left upper frontal gyrus, right upper frontal gyrus and middle frontal gyrus. The analyses on the facial emotion cognitive task and brain imaging data of the patient group showed that the slope data were positively correlated with grey matter volumes of the right superior temporal gyrus, middle temporal gyrus, left middle temporal gyrus, inferior temporal gyrus and fusiform gyrus.

Conclusion: There are general impairments in the neuro-cognitive functions and facial emotion cognitive functions of patients with first-episode schizophrenia, and the results suggest that brain areas with abnormal grey matter volumes are likely to be the brain structure and functional basis of the cognitive impairments.

背景:认知功能障碍是精神分裂症的核心症状之一，其康复程度与患者能否成功重返社会密切相关。目的:研究精神分裂症患者认知功能与脑灰质体积的关系。方法:对37例首发精神分裂症患者(患者组)和30例健康对照(对照组)的神经认知功能进行时钟绘制测试、轨迹标记测试、数字广度测试、听觉语言学习测试、威斯康星卡片分类测试、语言流畅性测试、语义相似度测试和Stroop颜色-单词测试。采用面部情绪认知任务评估32例首发精神分裂症患者(患者组)和29例健康对照(对照组)的面部情绪认知功能。采用阳性和阴性症状量表(PANSS)对首发精神分裂症患者的精神病症状进行评估。采用磁共振成像(MRI)采集患者组和对照组的脑成像数据。结果:患者组与对照组在时钟绘制测验、轨迹标记测验、数字广度测验、听觉言语学习测验、威斯康辛卡片分类测验、言语流畅性测验、语义相似测验和Stroop色字测验的反应时间上差异有显著性。两组在面部情绪认知任务中的斜率也存在显著差异。通过对比患者组与对照组脑灰质体积，发现患者组左侧额上回灰质体积增加，左侧枕回、舌回、小脑上部灰质体积减少。通过对患者组神经认知数据和脑成像数据的分析，Stroop颜色-单词测试C卡答对次数得分与左额上回、右额上回和额中回灰质体积呈负相关。对患者组面部情绪认知任务和脑成像数据的分析表明，斜率数据与右侧颞上回、颞中回、左侧颞中回、颞下回和梭状回灰质体积呈正相关。结论:首发精神分裂症患者的神经认知功能和面部情绪认知功能存在普遍的损伤，提示灰质体积异常的脑区可能是认知损伤的脑结构和功能基础。

{"title":"An Association Study on the Cognitive Function and the Cerebral Grey Matter Volume of Patients with First-Episode Schizophrenia.","authors":"Xinyue Zhang, Jingjing Yao, Yiding Lv, Xiaoxin Zhao, Yuan Li, Yuxiu Sui, Dai Zhiping","doi":"10.11919/j.issn.1002-0829.217138","DOIUrl":"https://doi.org/10.11919/j.issn.1002-0829.217138","url":null,"abstract":"Background: The impairment of cognitive function is one of the core symptoms in schizophrenia, and the degree of recovery is closely related to whether patients are able to rejoin society successfully.Objective: This study was to clarify the correlation between cognitive function and cerebral grey matter volume in schizophrenia.Methods: The neuro-cognitive functions of thirty-seven patients with first-episode schizophrenia (the patient group) and thirty healthy controls (the control group) was evaluated with the Clock Drawing Test, Trail Marking Test, Digit Span Test, Auditory Verbal Learning Test, Wisconsin Card Sorting Test, Verbal Fluency Test, Semantic Similarity Test and Stroop Color-Word Test. The facial emotion cognitive task was employed to assess the facial emotion cognitive functions of thirty-two patients with first-episode schizophrenia (the patient group) and 29 healthy controls (the control group). The psychotic symptoms of patients with first-episode schizophrenia were evaluated using the Positive and Negative Syndrome Scale (PANSS). The brain imaging data of the patient group and control group were collected using the magnetic resonance imagine (MRI).Results: The difference between the patient group and the control group in the results of Clock Drawing Test, Trail Marking Test, Digit Span Test, Auditory Verbal Learning Test, Wisconsin Card Sorting Test, Verbal Fluency Test, Semantic Similarity Test and Stroop Color-Word Test's reaction time were significant. These two groups' Slopes in the facial emotion cognitive task were also significantly different from each other. According to the comparison of cerebral grey matter volume between the patient group and the control group, it was found that the grey matter volume of the patient group increased in the left superior frontal gyrus, and decreased in the left occipital gyrus, lingual gyrus and upper cerebellum. Based on the analyses of neuro-cognitive data and brain imaging data of the patient group, the scores of the number of correct responses in Stroop Color-Word Test's Card C were negatively correlated with grey matter volumes of the left upper frontal gyrus, right upper frontal gyrus and middle frontal gyrus. The analyses on the facial emotion cognitive task and brain imaging data of the patient group showed that the slope data were positively correlated with grey matter volumes of the right superior temporal gyrus, middle temporal gyrus, left middle temporal gyrus, inferior temporal gyrus and fusiform gyrus.Conclusion: There are general impairments in the neuro-cognitive functions and facial emotion cognitive functions of patients with first-episode schizophrenia, and the results suggest that brain areas with abnormal grey matter volumes are likely to be the brain structure and functional basis of the cognitive impairments.","PeriodicalId":21886,"journal":{"name":"Shanghai archives of psychiatry","volume":"30 3","pages":"154-167"},"PeriodicalIF":0.0,"publicationDate":"2018-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.11919/j.issn.1002-0829.217138","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37045485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

The Effect of Repetitive Transcranial Magnetic Stimulation on the Reinstatement of Methamphetamine-Induced Conditioned Place Preference in Rats. 反复经颅磁刺激对大鼠甲基苯丙胺诱导的条件性位置偏好恢复的影响。

Shanghai archives of psychiatry

Pub Date : 2018-06-25 DOI: 10.11919/j.issn.1002-0829.218007

Xueqing Wu, Yunyue Ju, Dongliang Jiao, Min Zhao

Background: The abuse of methamphetamine (METH) has become a public health problem worldwide. This type of new drug can not only lead to addiction but can also cause cognitive impairment. Currently, there is no effective treatment. Repetitive transcranial magnetic stimulation (rTMS) is a painless and non-invasive green physiotherapy which can be used in the clinical treatment of neuropsychiatric disorders such as depression, anxiety, schizophrenia, and Parkinson's disease. However, whether it can be used to treat methamphetamine addiction is unclear.

Objective: To explore the effect of rTMS on the relapse behavior of methamphetamine addiction.

Methods: METH-induced rats conditioned place preference (CPP) model and rTMS technique were used in this study. Rats were given high frequency(10Hz) rTMS treatment for one day (experiment 1) or three days (experiment 2) after the extinction of CPP behavior. The reinstatement test was performed 24 hours after rTMS treatment and the effects of acute and chronic rTMS on the reinstatement of METH-induced CPP in rats were explored.

Results: Acute rTMS treatment (1 day) had a trend of an inhibitory effect on the relapse behavior of METH-induced CPP, but it was not statistically significant compared with the sham stimulation group (t=1.48, p=0.431). However, chronic rTMS treatment (3 days) had a significant inhibitory effect on the reinstatement of METH-induced CPP compared with the sham stimulation group (t=3.33, p=0.004).

Conclusion: Chronic rTMS treatment inhibited the relapse behavior of METH-induced CPP in rats.

背景:甲基苯丙胺(冰毒)的滥用已成为一个全球性的公共卫生问题。这种新药不仅会使人上瘾，还会引起认知障碍。目前尚无有效的治疗方法。重复经颅磁刺激(rTMS)是一种无痛、无创的绿色物理疗法，可用于临床治疗抑郁症、焦虑症、精神分裂症、帕金森病等神经精神疾病。然而，它是否可以用于治疗甲基苯丙胺成瘾尚不清楚。目的:探讨rTMS对甲基苯丙胺成瘾者复吸行为的影响。方法:采用冰毒诱导大鼠条件性位置偏好(CPP)模型和rTMS技术。大鼠在CPP行为消失后给予高频(10Hz) rTMS治疗1天(实验1)或3天(实验2)。在rTMS治疗24 h后进行恢复试验，探讨急性和慢性rTMS对冰毒诱导大鼠CPP恢复的影响。结果:急性rTMS治疗(1 d)对meth诱导的CPP复发行为有抑制作用的趋势，但与假药刺激组比较无统计学意义(t=1.48, p=0.431)。然而，慢性rTMS治疗(3 d)与假刺激组相比，对meth诱导的CPP恢复有显著的抑制作用(t=3.33, p=0.004)。结论:慢性rTMS治疗可抑制冰毒诱导大鼠CPP的复发行为。

{"title":"The Effect of Repetitive Transcranial Magnetic Stimulation on the Reinstatement of Methamphetamine-Induced Conditioned Place Preference in Rats.","authors":"Xueqing Wu, Yunyue Ju, Dongliang Jiao, Min Zhao","doi":"10.11919/j.issn.1002-0829.218007","DOIUrl":"https://doi.org/10.11919/j.issn.1002-0829.218007","url":null,"abstract":"Background: The abuse of methamphetamine (METH) has become a public health problem worldwide. This type of new drug can not only lead to addiction but can also cause cognitive impairment. Currently, there is no effective treatment. Repetitive transcranial magnetic stimulation (rTMS) is a painless and non-invasive green physiotherapy which can be used in the clinical treatment of neuropsychiatric disorders such as depression, anxiety, schizophrenia, and Parkinson's disease. However, whether it can be used to treat methamphetamine addiction is unclear.Objective: To explore the effect of rTMS on the relapse behavior of methamphetamine addiction.Methods: METH-induced rats conditioned place preference (CPP) model and rTMS technique were used in this study. Rats were given high frequency(10Hz) rTMS treatment for one day (experiment 1) or three days (experiment 2) after the extinction of CPP behavior. The reinstatement test was performed 24 hours after rTMS treatment and the effects of acute and chronic rTMS on the reinstatement of METH-induced CPP in rats were explored.Results: Acute rTMS treatment (1 day) had a trend of an inhibitory effect on the relapse behavior of METH-induced CPP, but it was not statistically significant compared with the sham stimulation group (t=1.48, p=0.431). However, chronic rTMS treatment (3 days) had a significant inhibitory effect on the reinstatement of METH-induced CPP compared with the sham stimulation group (t=3.33, p=0.004).Conclusion: Chronic rTMS treatment inhibited the relapse behavior of METH-induced CPP in rats.","PeriodicalId":21886,"journal":{"name":"Shanghai archives of psychiatry","volume":"30 3","pages":"188-198"},"PeriodicalIF":0.0,"publicationDate":"2018-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.11919/j.issn.1002-0829.218007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37045488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

上海精神医学

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀